Clearly define independent and dependent variable. Rresearch articles related to

Clearly define independent and dependent variable. Rresearch articles related to the variables to help the reader understand what is known about this topic. The literature review will be 10 pages in length.
1. Convert your personal quest into a
researchable topic
a. Personal Question:
What are the implications of spirituality and
the therapeutic applications of psilocybin in participants who suffer from
disorders of the mind limited to the spectrum of anxiety, PTSD, and the autism
spectrum?
b. Researchable Topic:
Therapeutic effects of psilocybin on anxiety, PTSD, and autism
spectrum.
2. Change the perspective (from personal topic to topic
related to your discipline)
Treatment of
specific mental disorders through the controlled application/dosage of
psilocybin.
3. The list of words / phrases to do the search. (at least
five words / phrases)
a. treatment with psilocybin
b. CIA / governmental research psilocybin
c. effects of psilocybin in children with autism
d. Veterans use of alternative medicines for PTSD
e. animals and alternative societies use of psilocybin
4. Criteria for inclusion / exclusion of articles.
a. Documents from 2000 and later
b. Peer reviewed
c. Government research project / Military research
d. Alternative treatment for anxiety and trauma
e. Use by other religions, societies and species for
chemical regulation
Potentail References that could be used follow:
Passie T, Seifert J, Schneider U, Emrich HM. The pharmacology of
psilocybin. Addict Biology. 2002; 7 4: 357- 64.
DOI: 10.1080/1355621021000005937. PubMed PMID: 14578010.
Inaba DS. All arounders.: Cholewa E, von Radics E, Uppers,
downers, all arounders – physical and mental effects of psychoactive drugs. 8th
ed. Medford (OR): CNS Products, Inc; 2014. p 6.5- 6.11.
Baumeister D, Barnes G, Giaroli G, Tracy D. Classical hallucinogens
as antidepressants? A review of pharmacodynamics and putative clinical
roles. Ther Adv Psychopharmacol. 2014; 4 4: 156- 69.
DOI: 10.1177/2045125314527985. PubMed PMID: 25083275.
Carhart-Harris RL, Erritzoe D, Williams T, Stone JM, Reed LJ, Colasanti
A, et al. Neural correlates of the psychedelic state as determined by fMRI
studies with psilocybin. Proc Natl Acad Sci U S A. 2012; 109 6:
2138- 43. DOI: 10.1073/pnas.1119598109. PubMed PMID: 22308440.
Nichols DE. Hallucinogens. Pharmacol Ther.
2004; 101 2: 131- 81. DOI: 10.1016/j.pharmthera.2003.11.002.
PubMed PMID: 14761703.
Tittarelli R, Mannocchi G, Pantano F, Romolo FS. Recreational use,
analysis and toxicity of tryptamines. Curr Neuropharmacol.
2015; 13 1: 26- 46. DOI: 10.2174/1570159X13666141210222409.
PubMed PMID: 26074742.
Nichols DE. The Heffter Research Institute: past and hopeful
future. J Psychoactive Drugs. 2014; 46 1: 20- 6.
DOI: 10.1080/02791072.2014.873688. PubMed PMID: 24830182.
Studerus E, Kometer M, Hasler F, Vollenweider FX. Acute, subacute
and long-term subjective effects of psilocybin in healthy humans: a pooled
analysis of experimental studies. J Psychopharmacol.
2011; 25 11: 1434- 52. DOI: 10.1177/0269881110382466. PubMed
PMID: 20855349.
American Psychiatric Association. Diagnostic and statistical manual
of mental disorders. 4th text revision. Washington: American Psychiatric
Association; 2000.
Johansen PØ, Krebs TS. Psychedelics not linked to mental health
problems or suicidal behavior: a population study. J Psychopharmacol.
2015; 29 3: 270- 9.
DOI: 10.1177/0269881114568039. PubMed PMID: 25744618.
van Amsterdam J, Opperhuizen A, van den Brink W. Harm potential of
magic mushroom use: a review. Regul Toxicol Pharmacol.
2011; 59 3: 423- 9. DOI: 10.1016/j.yrtph.2011.01.006. PubMed
PMID: 21256914.
Griffiths RR, Richards WA, McCann U, Jesse R. Psilocybin can
occasion mystical-type experiences having substantial and sustained personal
meaning and spiritual significance. Psychopharmacology (Berl).
2006; 187 3: 268- 83. DOI: 10.1007/s00213-006-0457-5. PubMed
PMID: 16826400.
Hendricks PS, Johnson MW, Griffiths RR. Psilocybin, psychological
distress, and suicidality. J Psychopharmacol. 2015; 29 9: 1041-
3. DOI: 10.1177/0269881115598338. PubMed PMID: 26395582.
Substance Abuse and Mental Health Services Administration
[Internet]. Population Data/NSDUH [cited 2016. Jan 30]. Available
from: http://www.samhsa.gov/data/population-data-nsduh/reports
Griffiths R, Richards W, Johnson M, McCann U, Jesse
R. Mystical-type experiences occasioned by psilocybin mediate the
attribution of personal meaning and spiritual significance 14 months
later. J Psychopharmacol. 2008; 22 6: 621- 32.
DOI: 10.1177/0269881108094300. PubMed PMID: 18593735.
Grob CS, Danforth AL, Chopra GS, Hagerty M, McKay CR, Halberstadt AL, et
al. Pilot study of psilocybin treatment for anxiety in patients with
advanced-stage cancer. Arch Gen Psychiatry. 2011; 68 1: 71- 8.
DOI: 10.1001/archgenpsychiatry.2010.116. PubMed PMID: 20819978.
Wilcox JA. Psilocybin and obsessive compulsive disorder. J
Psychoactive Drugs. 2014; 46 5: 393- 5.
DOI: 10.1080/02791072.2014.963754. PubMed PMID: 25364991. [PubMed] [Google Scholar]
Moreno FA, Wiegand CB, Taitano EK, Delgado PL. Safety,
tolerability, and efficacy of psilocybin in 9 patients with
obsessive-compulsive disorder. J Clin Psychiatry. 2006; 67 11:
1735- 40. PubMed PMID: 17196053.
Bogenschutz MP, Forcehimes AA, Pommy JA, Wilcox CE, Barbosa P, Strassman
RJ. Psilocybin-assisted treatment for alcohol dependence: a
proof-of-concept study. J Psychopharmacol. 2015; 29 3: 289- 99.
DOI: 10.1177/0269881114565144. PubMed PMID: 25586396.
Johnson MW, Garcia-Romeu A, Cosimano MP,
Griffiths RR. Pilot study of the 5-HT2AR agonist psilocybin in the
treatment of tobacco addiction. J Psychopharmacol. 2014; 28 11:
983- 92. DOI: 10.1177/0269881114548296. PubMed PMID: 25213996.